KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Income from Continuing Operations (2019 - 2025)

Aurinia Pharmaceuticals' Income from Continuing Operations history spans 7 years, with the latest figure at 210790000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 14650.87% year-over-year to 210790000.0; the TTM value through Dec 2025 reached 287198000.0, up 4893.01%, while the annual FY2025 figure was 287157000.0, 4892.3% up from the prior year.
  • Income from Continuing Operations reached 210790000.0 in Q4 2025 per AUPH's latest filing, up from 31551000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 210790000.0 in Q4 2025 to a low of 50379000.0 in Q1 2021.
  • Average Income from Continuing Operations over 5 years is 3710400.0, with a median of 12469500.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: plummeted 94.27% in 2021, then surged 14650.87% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 33322000.0 in 2021, then increased by 21.84% to 26046000.0 in 2022, then decreased by 3.15% to 26867000.0 in 2023, then skyrocketed by 105.32% to 1429000.0 in 2024, then soared by 14650.87% to 210790000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Income from Continuing Operations are 210790000.0 (Q4 2025), 31551000.0 (Q3 2025), and 21513000.0 (Q2 2025).